<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74013">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02097043</url>
  </required_header>
  <id_info>
    <org_study_id>DA7218_PK_I</org_study_id>
    <nct_id>NCT02097043</nct_id>
  </id_info>
  <brief_title>Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers</brief_title>
  <official_title>A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I clinical trial for evaluating the pharmacokinetics and
      safety/tolerability of DA-7218 in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve from time zero to the last quantifiable concentration by linear trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax, AUCinf, t1/2, CL/F, Vz/F (F; calculated in group 1)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events (subjective or objective symptoms)</measure>
    <time_frame>14 days(group 1), 7 days(group 2,3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs</measure>
    <time_frame>14 days(group 1), 7 days(group 2,3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination</measure>
    <time_frame>14 days(group 1), 7 days(group 2,3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>14 days(group 1), 7 days(group 2,3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>14 days(group 1), 7 days(group 2,3)</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[Group 1] DA-7218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg, By mouth or orally (PO) &amp; intravenous(IV) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Group 1] Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, By mouth or orally (PO) &amp; intravenous(IV) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Group 2] DA-7218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg, By mouth or orally (PO) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Group 2] Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, By mouth or orally (PO) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Group 3] DA-7218</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600mg, By mouth or orally (PO) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[Group 3] Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, By mouth or orally (PO) administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-7218</intervention_name>
    <arm_group_label>[Group 1] DA-7218</arm_group_label>
    <arm_group_label>[Group 2] DA-7218</arm_group_label>
    <arm_group_label>[Group 3] DA-7218</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>[Group 1] Placebo</arm_group_label>
    <arm_group_label>[Group 2] Placebo</arm_group_label>
    <arm_group_label>[Group 3] Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male Korean 19-45 years

          -  Body weight:55-90kg, BMI:18.0-27.0

        Exclusion Criteria:

          -  Present condition or history of any clinically significant disease

          -  Clinical evidence or history of GI disease or history of GI surgery

          -  History of hypersensitivities, including drug allergies

          -  AST (SGOT) or ALT (SGPT) &gt; 1.5 times the upper normal limit

          -  Systolic blood pressure : &lt;100 mmHg or &gt;160 mmHg

          -  Diastolic blood pressure : &lt;60 mmHg or &gt;100 mmHg

          -  Drug abuse within 2 months, or a positive reaction to an abusive drug or cotinine

          -  Taken any ETC or herbal supplement within 2 weeks or any OTC or vitamin supplement
             within 1 week

          -  Participation in and administration of IP of another clinical trial within 2 months

          -  Donation of whole blood within 2 months, or blood components within 1 month, or
             receipt of blood transfusion within 1 month

          -  Consumption of more than 21 units of alcohol/week or inability to abstain from
             drinking during the study period

          -  Smoking within 3 months

          -  Taking caffeine- or grapefruit-containing products within 3 days

          -  Plan to be pregnant, or not to use an appropriate method of contraception
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine / Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung Sang Yu, M.D., Ph.D.</last_name>
    <phone>+82-2-2072-1920</phone>
    <email>ksyu@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kyung Sang Yu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
